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Ovatodiolide suppresses colon
tumorigenesis and prevents polarization
of M2 tumor-associated macrophages
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Abstract
Background: An increased expression of Yes-associated protein (YAP1) has been shown to promote tumorigenesis
in many cancer types including colon. However, the role of YAP1 in promoting colon tumorigenesis remains unclear.
Here, we demonstrate that YAP1 expression is associated with M2 tumor-associated macrophage polarization and the
generation of colon cancer stem-like cells. YAP1 downregulation by gene silencing or a phytochemical, ovatodiolide,
not only suppresses colon cancer tumorigenesis but also prevents M2 TAM polarization.
Methods: Human monocytic cells, THP-1, and colon cancer cell lines, HCT116 and DLD-1, were co-cultured to mimic
the interactions between tumor and its microenvironment. M2 polarization of the THP-1 cells were examined using
both flow cytometry and q-PCR technique. The inhibition of YAP1 signaling was achieved by gene-silencing technique
or ovatodiolide. The molecular consequences of YAP1 inhibition was demonstrated via colony formation, migration,
and colon-sphere formation assays. 5-FU and ovatodiolide were used in drug combination studies. Xenograft and
syngeneic mouse models were used to investigate the role of YAP1 in colon tumorigenesis and TAM generation.
Results: An increased YAP1 expression was found to be associated with a poor prognosis in patients with colon
cancer using bioinformatics approach. We showed an increased YAP1 expression in the colon spheres, and colon
cancer cells co-cultured with M2 TAMs. YAP1-silencing led to the concomitant decreased expression of major
oncogenic pathways including Kras, mTOR, β-catenin, and M2-promoting IL-4 and tumor-promoting IL-6 cytokines.
TAM co-cultured colon spheres showed a significantly higher tumor-initiating ability in vivo. Ovatodiolide treatment
alone and in combination with 5-FU significantly suppressed in vivo tumorigenesis and less TAM infiltration in CT26
syngeneic mouse model.
Conclusions: We have identified the dual function of YAP1 where its suppression not only inhibited tumorigenesis but
also prevented the generation of cancer stem-like cells and M2 TAM polarization. Ovatodiolide treatment suppressed
YAP1 oncogenic pathways to inhibit colon tumorigenesis and M2 TAM generation both in vitro and in vivo.
Ovatodiolide should be considered for its potential for adjuvant therapeutic development.
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Background
Colorectal cancer (CRC) represents one of the most
prevalent malignancies in the world with an estimated
9% of all cancer incidence [1]. The pathogenesis of CRC
is complex due to many factors including environmental
risk factors, inherited genetic risks, and nutritional
practices [2]. The development of most CRC cases are
sporadic from dysplastic adenomatous polyps. These are
the results of several oncogenes such as KRas, c-myc, β-
catenin, and other less frequent but also powerful tumori-
genic pathways [3, 4]. Besides these genetic abnormalities,
the formation of an inflammatory microenvironment
also plays an essential role for CRC progression. Tumor-
associated macrophages (TAMs) as one of the most
abundant tumor-infiltrating stromal cell types have been
shown to promote metastasis, drug resistance, and asso-
ciated with a poor prognosis in CRC patients. Recent
studies suggest an intimate association between the gener-
ation and/or maintenance of cancer stem cells (CSCs) and
TAMs [5]. The presence of CSCs potentiates the epithelial-
to-mesenchymal transition (EMT), treatment resistance,
and tumor repopulation [5]. Thus, targeting TAMs
represents an important milieu for anti-cancer drug
development.
Yes-associated protein 1 (YAP1) is a well-established
oncogenic factor in hepatocellular carcinoma and recently
indicated in colorectal cancer [6–8]. YAP1 was proposed
to functioning either partially or in tandem with key onco-
genic drivers such as Kras, β-catenin, and Akt/mTOR in
colon tumor initiation and progression [6, 8, 9]. However,
the role of YAP1 and the tumor microenvironment
remains unclear. In this study, we investigated the role
of YAP1 in promoting colon tumorigenesis in tumor
cells and association with M2 TAM polarization. We
hypothesize that oncogenic YAP1 promotes the gener-
ation of M2 TAM polarization and in return M2 TAM
further enhances tumorigenic phenotypes including en-
hanced proliferation, colony formation, colon-sphere
generation, and metastatic potential. Therefore, agents
that target and suppress the expression of YAP1-
mediated signaling may act as a dual anti-cancer agent
by disrupting the molecular connections between TAMs
and tumor cells.
Ovatodiolide (OV) is a bioactive phytochemical puri-
fied from Anisomeles indica (L.) Kuntze (Labiatae), a
medicinal herb which has been widely used for the treat-
ment of a variety of inflammation-associated diseases
and implicated for potential anti-cancer functions by our
previous reports [10, 11]. Various oncogenic targets
inhibited by ovatodiolide have been implicated; these
include TNF-α, NF-κB, β-catenin, MMPs, and others to
achieve anti-cancer effects such as the induction of cell
cycle arrest, apoptosis, and reduction of metastatic poten-
tial [12–15]. Since the connection between inflammation
(TAMs) and colon tumorigenesis has been well estab-
lished, we aimed to examine the potential functions of
ovatodiolide (being an anti-inflammatory and anti-cancer
agent) in targeting both tumor cells and TAMs.
Results
Increased YAP1 expression is associated with poor
prognosis
We explored the public databases to show that YAP1 net-
work is upregulated in clinical colon cancer samples and
cell lines. First, in Sabates-Bellver colon database [16],
composing of 64 clinical samples from different regions,
YAP1 messenger RNA (mRNA) was significantly elevated
in both colon and rectal adenoma samples (Fig. 1a). In
Kaiser colon database analysis (Fig. 1b), comparing normal
colon tissues and colon adenocarcinoma, we found that
YAP1 mRNA was approximately 2.2-fold higher in the
adenocarcinoma samples [17]. Consistently, an elevated
YAP1 immunostaining was detected in the paraffin-fixed
sections from a small cohort of colorectal cancer patients
(Right panel, Fig. 1c, i). In normal colon tissue sections,
YAP1 staining appears to be low to medium in the epithe-
lial and glandular cells and low in the nerve/peripheral
ganglion (Left panel, Fig. 1c, i) (images obtained from
ProteinAtlas database, CAB009370). Our tissue micro-
array analysis supported that YAP1 expression was found
in normal colon crypts and a significantly increased signal
was identified in the rectal adenocarcinoma section
(Fig. 1c, ii). Consistently, using the online bioinformatics
tool SurvExpress, with the default setting, a higher YAP1
expression was associated with a significantly shorter time
of recurrence (Fig. 1d) [18]. In addition, the IL-6/YAP
signaling has been shown to be associated with increased
stemness in breast cancer [19]. In the same database,
patients with high risk of recurrence showed a signifi-
cantly higher IL-6 and YAP1 mRNA level (upper panel,
Fig. 1e); in a larger database (Colon Metabase, SurvEx-
press), a higher expression of IL-6 and YAP1 predicts a
lower survival rate (lower panel, Fig. 1e). In support, using
a colon tissue microarray, we identified a strong YAP1
expression in the late stages (stages IIIB, IIIC, IVA, and
IVB) colon cancer samples (Fig. 2). Furthermore, a recent
clinical study demonstrated that YAP1 activation was asso-
ciated with the poor prognosis and certuximab resistance
in colon cancer patients [20]. Collectively, these findings
support our hypothesis that YAP1 represents a key target
for therapeutic development in colon cancer patients.
Tumor-associated macrophages (TAMs) promote the
generation of CD133+ and side-population stem-like cells
and associated with increased YAP expression
Tumor-associated macrophages (TAMs) are implicated
in the development and progression of colorectal cancer
[21]. Here, we investigate the role of TAMs in generating
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Fig. 1 Increased YAP1 expression is associated with colon cancer malignancy. a Using public database, we first found that YAP1 mRNA expression is
elevated (at least 2-fold increase) in colorectal adenoma samples as compared to normal tissues (Sabates-Bellver database). b Another database (Kaiser
Colon database) indicated that YAP1 mRNA was significantly increased in a cohort of colon adenocarcinoma samples. c An increased YAP1 protein
expression profile was supported by clinical sample database (i, Antibody CAB009370, ProteinAtlas.org); ii. Our immunohistochemical analysis also
showed that YAP1 expression in normal colon crypts and a significantly increased YAP1 expression was found in the rectal adenocarcinoma section.
The number indicates the area of magnified view. d YAP1 expression was also found to be associated significantly to time of disease
recurrence [19]. e Patients with higher risk for colon cancer demonstrate both high YAP1 and IL-6 expression (upper panel); patients with
combined high expression of IL-6 and YAP1 were found to be associated with a significantly lower specific survival rate (Colon Metabase,
SurvExpress). P values are indicated in each panel
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drug-resistant CRC cells. Both DLD-1 and HCT116 cells
were co-cultured with TAMs and subjected to flow cyto-
metric analysis. We found that in the presence of TAMs,
the percentage of CD133+ (Fig. 3a) and side-population
cells (Fig. 3b) in both DLD-1 and HCT116 were signifi-
cantly increased. TAM co-cultured CRC cells showed
markedly increased colony-forming (Fig. 3c), migratory
(Fig. 3d), and self-renewal (Fig. 3e) abilities as compared
to their naïve counterparts. The increased tumorigenic
phenotypes by TAM co-culture was associated with a
higher expression in YAP1, ERK, Akt/mTOR (onco-
genic makers), and β-catenin (both oncogenic and
stemness marker) (Fig. 3g). More importantly, TAM
co-culture resulted in increased resistance toward 5-
FU treatment (Fig. 3f ). For instance, in the presence
of TAM, the IC50 value of 5-FU of DLD-1 was
approximately 11-fold higher than its naïve counter-
part (85.6 versus 7.73).
Fig. 2 YAP1 expression profile in colon cancer tissue microarray. A significantly increased staining of YAP1 was predominately found in the colon
cancer samples. Strong staining (Q score ≥150) was found in stages IIIB, IIIC, IVA, and IVB suggesting that YAP1 expression may be associated
with the progression of colon CA. Total number of samples (cancer 39 and normal tissues 9). a Representative micrographs of the tissue
microarray are shown (stained with YAP1 antibody). b Quantitative analysis of YAP1 staining. The Q score of each sample was plotted and
showed that strong YAP1 staining was associated in the tumor samples as compared to the normal tissues. ***P < 0.001. Scoring analysis was
performed using Q score as established previously [49]
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Fig. 3 (See legend on next page.)
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TAM educated CRC cells showed enhanced tumor-
initiating ability
TAM-enhanced tumor-initiating ability was tested in vivo.
Tumor spheres generated from naïve DLD-1 and from
TAM co-cultured DLD-1 (termed + TAM) were injected
subcutaneously into NOD/SCID mice to evaluate their
tumor-initating potential. We found that the+TAM group
initiated tumor growth significantly faster as compared to
their naïve counterparts (Fig. 4a). Fold change in tumor
size was measured semi-quantitatively based on the biolu-
minenesce signals; a significantly heavier tumor weight
was found in the+TAM group, reflecting the increased
tumorigenesis (Fig. 4b). In agreement with our in vitro
data, +TAM tumor sample showed an increased level of
YAP1, Kras, Akt/mTOR, NF-kB (oncogenic markers), and
β-catenin (both oncogenic and stemness marker, Fig. 4c).
Ovatodiolide treatment suppresses tumorigenesis in
CRC cells
We intend to identify compounds which not only target
cancerous cells but also TAMs, in contrast to the conven-
tional chemotherapeutic agents which only aim to elimin-
ate cancerous cells. Previously, studies from us and others
showed ovatodiolide (OV) as an anti-inflammatory and
anti-cancer agent in different cell models [10, 22, 23].
Here, we first demonstrated that OV effectively inhibited
the cell viability of HCT116 and DLD-1 colon cancer cells
(Fig. 5a). In addition, OV treatment significantly inhibited
the colony formation (Fig. 5b) and migration (Fig. 5c). We
subsequently showed that OV treatment suppressed the
self-renewal ability of CRC cells under serum-deprived
condition as reflected by the significantly lower number of
colon spheres formed (Fig. 5d). OV-mediated anti-CRC ef-
fects were found in association with the decreased expres-
sion of YAP1, Kras/MEK/ERK, NF-kB, mTOR (oncogenic
markers), β-catenin, and Notch1 (stemness markers) while
an increased in Bax expression (pro-apoptosis marker).
Ovatodiolide treatment suppresses M2 polarization
in vitro
After establishing ovatodiolide’s anti-CRC effects, we
examined if it could also prevent the generation of M2-
polarized tumor-associated macrophages (M2-TAMs),
known to promote tumor progression in many cancer
types including colon [24]. Human monocytic THP-1
cells were used as the macrophage precursor for our
study. Ovatodiolide treatment prevented M2 polarization
in THP-1 cells (Fig. 6a), as reflected by the significantly
decreased M2 markers (ARG1 and CD23) while no
significant difference in M1 markers (CD64 and CCR7).
We then demonstrated that ovatodiolide treatment led
to the decreased expression of YAP1, β-catenin, Atk,
and NF-kB in the M2 TAMs as compared to their un-
treated counterparts (Fig. 6b). One of the major cyto-
kines secreted by M2-TAM is IL-6, and IL-6’s oncogenic
roles have been well established in different cancer types
including colon cancer [25, 26]. Notably, M2 TAMs
express an elevated level of IL-6, and ovatodiolide treat-
ment significantly decreased IL-6 expression (Fig. 6b).
To explore if ovatodiolide treatment can suppress IL-
6-induced colon carcinogenesis, exogenous IL-6 was
introduced to the culture medium. We showed that the
addition of IL-6 significantly increased the expression of
multiple oncogenic markers including Kras-MEK, YAP1,
NF-kB, vimentin (EMT marker), β-catenin (a marker for
both oncogenesis and stemness), and ABCG2 (drug re-
sistance) in both HCT116 and DLD-1 cells. Ovatodiolide
treatment significantly suppressed these IL-6-induced
pathways (Fig. 6c). For instance, major pro-M2 TAM
polarization cytokines, IL-4 and IL-13 expression, were
markedly suppressed by the OV treatment even in the
presence of IL-6 (Fig. 6c).
IL-6 treatment significantly induced the generation of
colon spheres (Fig. 6d), and the addition of OV markedly
reduced this effect (Fig. 6d). IL-6-enhanced tumor
sphere-forming ability was disrupted significantly as the
size and the number of formed spheres was significantly
less comparing to IL-6-induced counterparts (Fig. 6d).
In support, exogenous IL-6 resulted in an increase in
CD133+ HCT116 and DLD-1 cells. The addition of
ovatodiolide (in the presence of IL-6) significantly re-
duced the IL-6-induced effects (Fig. 6e). Furthermore,
we tested the possibility of ovatodiolide working in
synergy with 5-FU to suppress the viability of colon
cancer cells. Different concentration combinations of
ovatodiolide and 5-FU were assayed to generate the
isobolograms. We found that several combinations of
5-FU and ovatodiolide inhibited both HCT116 and
DLD-1 cell viability synergistically (CI index <1, in
bold, Fig. 6f ).
(See figure on previous page.)
Fig. 3 M2 TAM promotes colon tumorigenesis associated with increased YAP1 and associated oncogenic pathways. M2 TAM co-culture increased
CD133+ (a) and side-population (b) in HCT116 and DLD-1 cells, respectively. A representative side-population analysis is shown here. M2 TAM also
enhanced the colony-forming (c) and migratory (d) abilities in both HCT116 and DLD-1 cells. e Increased sphere formation. f SRB analysis demonstrates
a significant increase in the 5-FU resistance of the TMA co-cultured HCT116 and DLD-1 cells (right panel) as compared to their naïve counterparts (left
panel). The comparative IC50 values are listed in the table below (g) The enhanced tumorigenic ability is associated with an elevated expression of
oncogenic markers YAP1, Akt/mTOR, Erk, and colon stemness maker, β-catenin. The number beneath each band represents the expression ratio of
each signal normalized against actin (as 1). All experiments were done in triplicates
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Fig. 4 TAM co-culture increased tumor-initiating ability in vivo. a DLD-1 cells co-cultured with M2 TAMs were subsequently cultured under
serum-deprived conditions to generate DLD-1 spheres. DLD-1 + TAM group initiated tumor growth significantly faster than its naïve counterparts.
Representative bioluminescence images are shown (N = 5 per group). b Semi-quantitative bioluminescence comparison between DLD-1 + TAM and
naïve groups. Fold change in tumor size was indicated by the fold change in bioluminescence intensity over time. Tumor growth (represented as fold
change in bioluminescence intensity, BLI) was significantly higher in the DLD-1 + TAM group, *P < 0.05. The upper right panel shows the significantly
higher average tumor weight collected from DLD-1 + TAM group as compared to its naïve counterparts, **P < 0.01. The lower right panel shows body
weights of both groups over time. c Western blot analysis of tumor biopsies indicated that DLD-1 + TAM sample exhibited a markedly increased YAP1,
Akt/mTOR, NF-kB, and Kras signaling. The expression intensity was compared using arbitrary ratios normalized against β-actin (as 1)
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YAP1-silencing led to decreased CRC tumorigenesis and
M2 polarization
Subsequently, YAP1 expression was downregulated using
siRNA technique in both HCT116 and DLD-1 cells (Fig. 7a);
stemness markers (YAP1, β-catenin), oncogenic markers
(Kras, Akt/mTOR), drug resistance marker (ABCG2), pro-
M2 polarization cytokines (IL-4 and IL-13), and mesenchy-
mal marker (vimentin) were downregulated in the wake
of YAP1 silencing. These observations were comparable




Fig. 5 Ovatodiolide treatment suppresses CRC tumorigenesis and colon sphere generation. a Cell viability assay (SRB) demonstrates that ovatodiolide
is effective in suppressing cell viability in CRC cell lines. The IC50 values are indicated. The insert depicts the 2D chemical structure of
OV (diagram adapted from PubChem CID 6451060; molecular formula C20H24O4; molecular weight 328.40216 g/mol). OV (OV 2.8 μM approximately
IC10) effectively suppresses colony-forming (b), migratory (c), and self-renewal (d) abilities of both HCT116 and DLD-1 CRC cell lines. **P < 0.01.
e OV-mediated inhibitory effects on CRC cells were associated with the decreased expression of YAP1, Kras/MEK/ERK, NF-kB, mTOR (oncogenic
markers), β-catenin, Notch1 (stemness markers), and increased Bax (apoptosis marker). OV treatment (14 μM, 48 h, 1 × 106 HCT116 and DLD-1 cells).
The number beneath each band represents the expression ratio of each signal normalized against actin (as 1)
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Fig. 6 (See legend on next page.)
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phenotypes including colony formation (Fig. 7b), migra-
tion (Fig. 7c), sphere formation (Fig. 7d), and resistance
against 5-FU (Fig. 7e) were significantly suppressed in
YAP1-silenced cells. In addition, the percentage of CD133
+ cells were also markedly reduced in the YAP1-silenced
cells; more importantly, YAP1-silencing led to a less IL-6-
responsive cells as indicated by the lower percentage of
CD133+ cells under the exogenous IL-6 treatment
(Fig. 7f). When co-cultured with YAP1-silenced DLD-1
cancer cells, THP-1 monocytes differentiated into mac-
rophages expressing a significantly reduced M2 marker.
For instance, M2 markers such as ARG1 and CD23
were significantly lower than the THP-1 macrophages
differentiated under YAP1 wild-type DLD-1 cells (Fig. 7g).
Interestingly, the M1 markers such as CD64 and CCR7 did
not appear to be significantly affected. In support, THP-1
macrophages co-cultured with YAP1-overexpressing DLD-
1 or HCT116 cells resulted in an increased expression of
M2 markers (Additional file 1: Figure S2B).
Equally important, the number of CD133+ cells were
significantly increased in both YAP1-overexpressing
DLD-1 and HCT116 cells (Additional file 2: Figure
S1A); the tumor sphere-forming ability was also mark-
edly enhanced in YAP1-overexpressing cells (Additional
file 2: Figure S1B). In consistent with our proposed role
for YAP1, when YAP1 expression is increased so is the
level of β-catenin, NF-kB, vimentin, and Kras (Additional
file 2: Figure S1C).
The role of YAP1 in M2 polarization was also tested
in THP-1 cells by silencing YAP1 (Additional file 1:
Figure S2A). We found that the resultant macrophages
differentiated from YAP1-silenced THP-1 showed a
significantly reduced level of IL-4, TGFB1, and Ym2 (M2
markers) while increased iNOs (M1 marker).
OV treatment suppressed CRC tumorigenesis and M2
infiltration in vivo
The potential colon cancer suppressive effect of ovatodio-
lide was investigated in vivo using immune competent
mouse xenograft model with CT26 mouse colon cancer
cells. OV treatment (5 mg/kg, five times/week) appeared
to be as effectively in suppressing tumor growth as stand-
ard chemotherapeutic agent 5-FU (30 mg/kg, twice a
week) while the combined treatment yielded the most
significant tumor inhibitory effect (Fig. 8a, b). Immunohis-
tochemical analysis of the tumor samples revealed that
OV alone and OV + 5FU exhibited less number of M2
TAM, as reflected by the lower number of CD206+ cells
as compared to those in control tumor counterparts
(Fig. 8c); the tumor growth inhibitory effect of OV and
OV + 5-FU may be attributed to the reduced staining of
YAP1, mTOR, and β-catenin.
Discussion
Tumor-associated macrophages or TAMs (the M2-
polarized TMAs particularly) have been indicated to
promote tumorigenesis and drug resistance [27, 28]. The
increased abundance of tumoring infiltrating M2 TAMs
has been correlated with poor prognosis in various types
of human cancers including colon [24, 29, 30]. The
modification and/or disruption between the molecular
communications between colon cancer cells and its
microenvironment (TAMs) thus represents an important
milieu for intervention development. Here, we first
demonstrated that the presence of M2 TAMs promotes
the generation of cancer stem-like phenotypes in both
HCT116 and DLD-1 colon cancer cells; M2 TAM co-
cultured cancer cells demonstrates increased CD133
expression, colon sphere-forming ability in association
with a significantly resistant 5-FU resistance.
M2 TAMs have been shown to promote tumorigenesis
via the secretion of a plethora of cytokines [31]. One of
the major M2 TAM-secreted oncogenic cytokines, IL-6,
has been implicated in contributing metastatic potential
and therapeutic interventions in different cancer types
including colon [26, 32]. Our study adds another dimen-
sion of IL-6’s role in colon tumorigenesis where IL-6
from M2 TAMs or exogenous source enhanced the gen-
eration of colon stem-like cells (or colon spheres); the
addition of IL-6 was associated with an increased ex-
pression of several oncogenic pathways including YAP1,
Kras, β-catenin, NF-κB, and mTOR and the increased
expression of IL-4 and IL-13, both of which have been
established for the promotion of M2 phenotype [33].
Experimental and clinical evidence indicate that targeting
and eliminating TAMs represent a potential therapeutic
(See figure on previous page.)
Fig. 6 Ovatodiolide treatment suppresses the M2 TAM polarization. a Macrophage progenitor cells, THP-1 cells, were cultured under M2 macrophage
conditional medium with and without the treatment of ovatodiolide (OV, 14 μM, 48 h). Real-time PCR analysis demonstrated that the addition of OV
significantly decreased the M2 markers including ARG1 and CD23 while not affecting M1 polarization in the differentiated macrophages. b Western
blot analysis of OV-treated macrophages demonstrated decreased YAP1, NF-kB, phosphorylated-Akt/Akt, and IL-6. THP-1 served as a control for M2
TAMs. The minus sign indicates M2 TAMs without OV treatment while the plus sign indicates M2 TAMs treated with OV (14 μM, 48 h). c IL-6 addition
simulates the presence of M2 TAMs promoted colon tumorigenic profiles including enhanced Kras, b-catenin, YAP1, NF-kB, and Atk/mTOR signaling;
the addition of OV significantly reversed IL-6 induced tumorigenic profiling. d The addition of IL-6 markedly enhanced the formation of colon spheres
in both cell lines, and the OV treatment suppressed it. e OV treatment markedly reduced IL-6-induced CD133+ cell population in both HCT116 and
DLD-1 cell lines. f The combination index (CI) analysis showed that 5-FU and OV synergistically inhibited both DLD-1 and HCT116 cell viability.
Synergism (CI < 1, shown in bold font), additive effect (CI = 1), and antagonism (CI > 1). All experiments were performed in triplicates
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strategy of cancer therapy [34, 35]. However, previous stud-
ies suggested that targeting M2 TAMs systemically carries
the risk of compromising the host’s immunity [27, 36, 37].
Here, we identified YAP1 as a potential molecule whose
expression is associated with M2 polarization and colon
tumorigenesis. First, an increased YAP1 expression was
detected in colon spheres and M2 TAMs. Second, the
downregulated YAP1 expression in colon cancer cells by
either gene-silencing technique or phytochemical treatment
of ovatodiolide led to the decreased tumorigenesis
(colony formation, migration, and tumor sphere formation)
accompanied by the decreased M2-polarizing cytokines
such as IL-4 (the major one affected by YAP1 silencing)
and IL-13 (to a lesser extent) as well as mTOR/Akt signal-
ing. Our observation was supported by a study indicating
that IL-4/IL-13/Akt [38–40] signaling axes are important
for M2 phenotype generation.
In parallel, ovatodiolide treatment suppressed YAP1
along with other major oncogenic pathways and pre-
vented the THP-1 monocytes from M2 polarization in
association with a decreased oncogenic cytokine IL-6
expression. Notably, IL-6 has been shown to contribute
Fig. 7 YAP1 silencing significantly decreased CRC tumorigenesis and M2 TAM generation. a Western blot analysis demonstrated YAP1 downregulation
using siRNA versus vector control (VC). b YAP1 silencing in both DLD-1 and HCT116 cells were associated with a marked decreased expression of
several key oncogenic pathways, Kras, NF-kB, mTOR, and β-catenin as well as the pro-M2 cytokine IL-4. c–e YAP1-silencing also led to the decreased
migratory, colony-forming, and sphere-generating abilities in both cell lines, respectively. **P < 0.01, *P < 0.05. f Flow cytometric analysis showed
YAP1-silencing significantly reduced the percentage of CD133+ cells in both cell lines even with the exogenous IL-6 stimulation. g Comparative M2
polarizing ability between THP-1 macrophages co-cultured with YAP1 wild-type (WT) and YAP1-knockeddown (KD) DLD-1 cells. Real-time PCR analysis
demonstrates that the M2-polarization process was significantly reduced in THP-1 cells (co-cultured with YAP1-KD DLD-1 cells) as indicated by the
significantly reduced M2 markers (ARG1 and CD263) while M1 phenotype was not affected. NS denotes not significant
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to proliferation and promote EMT and self-renewal in
breast cancer cells [27] establishing an essential commu-
nication between cancer cells and M2 TAMs. We
showed that exogenous IL-6 led to the increased gener-
ation of colon tumor spheres with concomitant elevated
YAP1 expression, establishing a novel link between
YAP1 and IL-6 network. Moreover, bioinformatics ana-
lysis (data not shown) indicated that downregulation of
YAP1 is associated with a decreased level of IL-10RB
(Interleukin-10 receptor subunit beta) implicating their
collaborative roles in M2 polarization process. Together,
our data suggests that YAP1’s function in promoting
colon tumorigenesis not only derives from its intrinsic
oncogenic properties but also functions to promote M2
TAM polarization. Interestingly, previous report indi-
cated that oncogenic Kras, YAP1, and β-catenin serve
similar functions in cell cycle control in tumor initiation
[8]. A recent seminal study showed that acquired resist-
ance against Kras inhibition in a Kras-driven mouse lung
cancer model was associated with an increased YAP1
signaling; Kras and YAP1 signaling converges and
activates the cellular EMT machinery [41]. This is in
Fig. 8 Ovatodiolide suppressed tumorigenesis and macrophage infiltration in vivo. a In vivo evaluation of tumor growth suppressive effect.
Ovatodiolide (5 mg/kg, five times/week), 5-FU (30 mg/kg, two times/week), and combination regimen were evaluated. Tumor inhibitory effect
was the most significant in the combination group followed by OV and 5-FU alone groups. The bodyweight of the animals were not negatively
affected except for the 5-FU group. b Photographs and average weight of tumor samples collected from each group. c Immunohistochemical
staining of tumor sample sections. Oncogenic YAP1, mTOR, and β-catenin and CD206 (M2 marker) expression was most significantly suppressed
in the combination group followed by OV and 5-FU group. The numbers indicate the average number of CD206+ cells (three random fields were
counted and averaged). d Schematic diagram illustrating the anti-CRC effect by OV treatment is 2-fold, targeting both oncogenic pathways in
colon cancer cells and the generation of M2 TAMs in the microenvironment
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agreement of our finding that YAP1 suppression either
by ovatodiolide or gene silencing significantly reduced
the expression of Kras and oncogenic properties (includ-
ing sphere-forming ability).
The anti-cancer and self-renewal properties of ovato-
diolide have been previously established by our group
[10, 15, 22]. The present study furthered the exploration
of ovatodiolide’s anti-cancer function by showing its
effects on preventing the generation of M2 TAMs. In
this study, we identified the elevated YAP1 expression in
M2 TAMs and ovatodiolide treatment prominently
suppressed the expression of YAP1, M2 markers (ARG1
and CD23), and inflammatory-signaling networks such
as NF-κB and Akt. Our findings suggest that YAP1
within the tumor cells may function in promoting colon
tumorigenesis via its association with aforementioned
oncogenic pathways and generating cancer stem-like
cells (as shown in our study) while generating M2 TAMs
via increased M2-polarizing IL-4 and IL-13 cytokines
into the stroma (Fig. 8d for proposed model). In addition,
ovatodiolide-mediated IL-6 suppression in the M2 TAMs
represented another important anti-cancer attribute of
ovatodiolide; even in the presence of exogenous IL-6
which increased the generation of cancer stem-like cell
population in both HCT116 and DLD-1 cell lines, ovato-
diolide was able to attenuate IL-6’s effects.
Certainly, ovatodiolide-mediated anti-cancer effects in
this study appeared to be multi-targeted and differential
between HCT116 and DLD-1 cells. This reflects the
heterogeneity of cancer and the importance of precision
medicine. HCT116 and DLD-1 cells used in this study
share a very similar gene mutation profile. But one of
the major difference is that DLD-1 is a TP53 mutant
while HCT116 wild-type. This may explain that HCT116
is slightly more sensitive toward ovatodiolide’s treatment;
HCT116 also contains a lower intrinsic YAP1 expression
level as compared to DLD-1 and demonstrates a lower
ability to form tumor spheres as compared to DLD-1. A
recently study indicated that primary breast cancers
harboring TP53 mutations and expressing high level of
YAP1 demonstrate a higher expression level of cyclin A,
cyclin B, and CDK1 genes as compared to the TP53 wild-
type counterparts [42]. It warrants further investigations
to determine if this phenomenon also exists in colon
cancer and for establishing a colon cancer signature for
ovatodiolide sensitivity.
Conclusions
Here, we demonstrated for the first time that YAP1
played a key role in colon tumorigenesis in a dual
dimensional fashion where it acts in cancer cells to
promote the malignant phenotypes including cancer
stem-cell like properties and in polarizing TAMs toward
M2 phenotype. The suppression of YAP1 either by siRNA
or ovatodiolide suppressed YAP1-associated oncogenic
characteristics. Thus, YAP1 could represent an important
druggable target; ovatodiolide could be further evaluated
and considered to be used as an adjuvant agent for
treating colon cancer.
Methods
Cell culture and chemicals
The human colon cancer cell lines HT-29, SW480,
DLD-1, HCT116, and monocytic cell line, THP-1, were
obtained from the American Type Culture Collection
(ATCC), and cells were cultured according to ATCC’s
recommended conditions. Colon sphere formation assay
was performed according to previously established method
[43]. DLD-1 and HCT116 cells were cultured in Serum-
Free Medium (SFM) composed of DMEM/Ham’s F12 (1:1),
human epidermal growth factor (hEGF, 20 ng/ml), basic
fibroblast growth factor (bFGF; 10 ng/ml (PeproTech, NJ,
USA), 2 μg/ml of 0.2% heparin (Sigma), and 1% penicillin/
streptomycin (P/S, 100 U/ml, Hyclone). Cells were
seeded (1000 cells/ml) in 12-well low adhesion plates
and incubated at 37 °C and 5% CO2 for 5–7 days.
Cell aggregates or spheroids (compact, spherical, non-
adherent masses >50 μM in diameter) were counted.
5-FU was purchased from SelleckChem, Taiwan (Cat.
No.S1209), and ovatodiolide was isolated and purified
as described previously [44].
Cell viability determination
Cellular viability in this study was determined using
the sulforhodamine B (SRB) assay [45]. Briefly, colon
cancer cells and/or spheres were seeded in 96-well
plates (3.5 × 105 cells/well) and treated with drugs of
interest (ovatodiolide or 5-FU) alone or in combin-
ation at indicated concentrations and times. Post
treatment, the relative cell number was determined
using a SRB reagent according to the manufacturer’s
protocol (Sigma, USA). For tumor spheres or non-
attached cells, the cell viability was quantified using
Alamar blue staining (Life Technologies, USA).
Macrophage generation and differentiation
Macrophage generation and differentiation from THP-1
cells were performed according to previously established
method [46]. In brief, for M2-polarized macrophages,
THP-1 cells were first treated with 320 nM PMA for
6 h, followed by cultured by the addition of IL-4 and IL-
13 (20 ng/ml) for another 18 h. For M1-polarized THP-
1 macrophages, LPS (100 ng/ml) and IFN-γ (20 ng/ml)
were used instead. THP-1 cells were also co-cultured
with CRC cell lines. CRC cells were seeded in the upper
insert of a six-well Transwell apparatus (0.4 μM pore
size, Corning, Lowell, MA) while THP-1 with 320 nM
PMA in the lower chamber. After 48 h, both macrophages
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and CRC cells were then harvested for further biochem-
ical analyses. In the colon cancer co-culture experiments,
only PMA was added to the THP-1 cells (M0 macrophage
progenitors) without the addition of IL-4 and IL-13. After
48 h of co-culture, both colon cancer cells and differenti-
ated macrophages were harvested for further analyses.
Flow cytometry analysis
Flow cytometry was used to profile CRC stem-like cells
using the BD Accuri™ C6 personal flow cytometer.
CD133/1 (AC133) antibodies conjugated to APC (Miltenyi
Biotec, Auburn, CA, USA) were used to determine CD133
+ CRC cells. Side-population analysis was performed
according to previously established method [47]. In brief,
side-population HCT116 and DLD-1 cells were identified
using FACSAria™ III sorter (BD Biosciences, Taiwan).
Verapamil (100 μM final concentration) was added
15 min before Hoechst incubation and was used as a
control. SP cells which express ATP-binding cassette
ABCG2 and Hoechst 33342 efflux activity was identified
and determined to be SP cells.
Real-time PCR reaction
The total RNA was isolated and purified using TRIzol-
based protocol (Life Technologies) according to the
vendor’s instructions. Ten nanograms of total RNA were
reverse transcribed using QIAGEN OneStep RT-PCR Kit
(QIAGEN, Taiwan), and the PCR reaction was carried
out using a Rotor-Gene SYBR Green PCR Kit (400,
QIAGEN, Taiwan). The primer sequences for q-PCR
experiments are as listed below:
(additional primer sequences may be found in Additional
file 1: Figure S2).
YAP1 silencing and overexpression
YAP1 expression was downregulated using siGNEOME
SMARTpool YAP1 siRNAs (Catalog No. M-012200-00,
Dharmacon). The gene-silencing experiments were car-
ried out according to vendor’s instructions. After each
gene-silencing experiment, western blots were used to
verify that YAP1 gene product was successfully knocked
down. YAP1 overexpression was performed by transfecting
the cells with YAP1 open-reading frame vector (human,
Cat. No. LV805163, Applied Biological Materials Inc., BC,
Canada). The transfection protocol was performed by
following vendor’s instructions.
Western blot analysis
Total colon cancer cell lysates obtained from different
experiments were separated using the SDS-PAGE using
Mini-Protean III system (Bio-Rad, Taiwan) and trans-
ferred onto PVDF membranes using Trans-Blot Turbo
Transfer System (Bio-Rad, Taiwan). The majority of the
primary antibodies used in this study were listed. YAP1
(#4912), mTOR (#2983), and β-catenin (#9562) from
Cell Signaling Techology (Taipei, Taiwan) and Kras
(12063-1-AP), IL-6 (21865-1-AP), and IL-4 (16545-1-
AP) from Protein Tech (Taipei, Taiwan). Secondary anti-
bodies were from Santa Cruz Biotechnology (Santa Cruz,
CA). Protein of interests were detected and visualized
using ECL detection kit. Images were obtained and ana-
lyzed using UVP BioDoc-It system (Upland, CA, USA).
Colony formation and migration assays
The colony-forming assay was performed using an
established protocol [48] with modifications. Briefly, 500
HCT116 and DLD-1 cells were seeded in six-well plates
with (2.8 μM ovatodiolide, equivalent of IC10 values) and
without ovatodiolide. The plates were then stained using
0.005% crystal violet, and the colonies were counted.
The cells were allowed to grow for another week. The
cells were then harvested, fixed, and counted. The mi-
gratory ability of the cells was examined using Transwell
migration assay (ThermoFisher, Taipei, Taiwan). In short,
cells were trypsinized and re-suspended in a serum-free
DMEM medium with or without treatments (siYAP or
ovatodiolide of different dosing regimens). The cells
were subsequently seeded into the upper chamber poly-
carbonate filters (8 μm pore size). A serum-containing
DMEM medium (500 μL) was added to the lower cham-
bers. The experiment was performed for either 24 or
48 h depending on the cell line. The cells were fixed
with 3.7% formaldehyde and stained with crystal violet.
The non-migratory cells on the upper side of the mem-
brane were removed. The migratory ability was deter-
mined as the number of cells calculated on the lower
side of the membrane.
In vivo experiments
Female NOD/SCID and BALB/c mice were purchased
from BioLASCO Taiwan Co., Ltd. The experiments were
conducted strictly in compliance to the Affidavit of Ap-
proval of Animal Use Protocol Taipei Medical University
(protocol LAC-2014-0170). First, the tumor-initiating
ability test was performed using the tumor spheres gen-
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DLD-1 cells. Spheroids cells (1 × 105 cells/injection) were
subcutaneously injected into the right flank of NOD/
SCID mice. DLD-1 expressing GFP and firefly luciferase
dual reporter system (L2G, a generous gift from Dr.
Sanjiv Sam Gambhir, Stanford University) was used for
the bioluminescence imaging experiments. Tumorigen-
esis was monitored using bioluminescence (IVIS 200
system, Caliper) on a weekly basis and quantified using
Living Imaging software. The tumor growth was indi-
cated by the fold change in bioluminescence intensity
plotted over time. Second, for drug treatment test and
examination of TAM infiltration, subcutaneous tumor
model was established using murine colon cancer cell
line, CT26 (1 × 106 cells/20 μL/injection) in BALB/c
mice (4–6-weeks old). The treatments commenced when
the tumor size reached approximately 100 mm3 mea-
sured by a standard caliper. Dosing regimens are as the
following: 5-FU alone (30 mg/kg, two times/week),
ovatodiolide alone (5 mg/kg, five times/week), and 5-
FU + ovatodiolide combination (30 mg/kg, two times/
week; 5 mg/kg five times/week, respectively). Both agents
were given intraperitoneally. The change in tumor burden
was expressed in fold change in cubic millimeter as
compared to its starting volume. Mice were humanely
sacrificed upon completion of experiment, and tumor
biopsies were collected for further analyses.
Immunohistochemical analysis
For preliminary screening, commercially available tissue
microarray slides (Category # BA5 and CDA3) were pur-
chased from SuperBioChips (Seoul, Korea). The staining
protocol was followed as per the vendor’s published in-
structions (UltravVision Quanto Detection System HRP
DAB manual, Thermo Sicentific, CA, USA). In short, the
immunostaining was performed on 5-μm-thick tissue
sections cut from the TMA (both commercially pur-
chased and in vivo tumor samples). The sections were
dewaxed and deparaffinized in xylene and rehydrated in
graded alcohol solutions. Antigen-retrieval process was
performed by heat-induction for 30 min in Tris-EDTA
buffer. Slides were subsequently stained with primary
antibodies of YAP1 (#4912, 1:400), mTOR (#2983,
1:500), β-catenin (#9562, 1:400, Cell Signaling technol-
ogy, Taiwan), CD206 (anti-mannose receptor antibody,
ab64693, 1: 400, Abcam, Taiwan), and their respective
secondary antibodies. The sections were then counter-
stained with hematoxylin, followed by dehydration and
mounting. The images were captured and recorded using
Tissue FAXS viewer software (TissueGnotics, GmBH,
Vienna, Austria).
Statistical analysis
All experiments were performed and repeated at least
three times. For in vitro experiments, bar charts and
graphs represent mean values, and error bar indicates
standard deviation (s.d). A paired “one-tailed” or ‘two-
tailed” Student’s t test was performed using GraphPad
Prism software. The result was considered significant
when *P < 0.05, **P < 0.001, and ***P < 0.001, respectively.
Additional files
Additional file 1: Figure S2. YAP1 expression is associated with M1-M2
polarization. (A) YAP1 silencing in macrophages (M0) leads to decreased
M2 polarization. Real-time PCR analysis demonstrates that M2 markers,
TGF-b1 and Ym2, were significantly reduced while one of the M1 marker
iNOS was significantly increased, in the macrophages generated in the
presence of DLD-1 cells. (B) YAP1-overexpressing colon cancer cells also
promote the polarization of M2 genotype in THP-1 cells. Experiments
were performed at least three times. *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001. The
primer sequences used in the q-PCR experiments are shown. (PPTX 109 kb)
Additional file 2: Figure S1. YAP1 overexpression (OE) leads to
increased stemness in colon cancer cells. (A) A significantly increased
CD133+ cell percentage was found in the YAP1 OE cells as compared to
their wild-type counterparts as demonstrated by our flow cytometric
analysis. (B) YAP1-overexpressing HCT116 and DLD-1 cells were found to
form a significantly higher number of tumor spheres (*P≤ 0.05, **P≤ 0.01).
(C) Comparative western blots of wild-type and YAP1 overexpressing
HCT116 and DLD-1 cells. An increased expression of β-catenin, NF-kB,
vimentin, and Kras is associated with YAP1 overexpression. (PPTX 396 kb)
Acknowledgements
We are grateful to the excellent technical supports from Hui-Hsien Chiang,
Li-Wen Wang, Min-Hao Ho, Cian-Ru Yang, and Po-Yang Huang.
Funding
This study was funded by the following agencies. (1) TMUTOP103003-8 from
Taipei Medical University, The Aim for the Top University Project, the Ministry
of Education, Taiwan, to Alexander TH Wu and Yan-Jun Huang. (2) MOST104-
2314-B-038-077-MY3 and MOHW105-TDU-B-212-134001 (Health and welfare
surcharge of tobacco products, Ministry of Health and Welfare, Taiwan) to Dr.
Whang-Peng Jacqueline and Excellence for Cancer Research (TMU-CECR).
Availability of data and materials
Please contact the author for data requests.
Authors’ contributions
YJH performed experiments and drafted the manuscript. ATHW, MH, TCM,
and YY designed the experiments and wrote the manuscript. CKY, PLW, TTH,
and JWP contributed to the study design and data analyses. YMT isolated/
purified the ovatodiolide and contributed to the study design. All authors
read and approved the final manuscript.
Competing interests




The experiments were conducted strictly in compliance to the Affidavit
of Approval of Animal Use Protocol Taipei Medical University (protocol
LAC-2014-0170).
Author details
1The PhD Program for Translational Medicine, College of Medical Science
and Technology, Taipei Medical University, Taipei, Taiwan. 2Division of
Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital,
Taipei Medical University, Taipei, Taiwan. 3Department of Surgery, College of
Medicine, Taipei Medical University, Taipei, Taiwan, People’s Republic of
China. 4Division of Colorectal Surgery, Department of Surgery, Mackay
Memorial Hospital, Taipei, Taiwan. 5Center for Molecular Biomedicine,
Huang et al. Journal of Hematology & Oncology  (2017) 10:60 Page 15 of 17
University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam. 6Division
of Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei,
Taiwan. 7Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
8Genomics Research Center, Academia Sinica, Taipei, Taiwan. 9Center for
General Education, National Taitung University, Taitung 95092, Taiwan. 10The
PhD Program of Cancer Biology and Drug Discovery, College of Medical
Science and Technology, Taipei Medical University, Taipei, Taiwan. 11Center
of Excellence for Cancer Research, Taipei Medical University, Taipei, Taiwan.
12Department of Life Science, National Taitung University, Taitung, Taiwan.
Received: 21 September 2016 Accepted: 14 February 2017
References
1. Boyle P, Langman JS. ABC of colorectal cancer: epidemiology. BMJ. 2000;
321(7264):805–8.
2. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence,
mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191–7.
3. Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med.
2002;137(7):603–12.
4. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW.
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in
beta-catenin or APC. Science (New York, NY). 1997;275(5307):1787–90.
5. Jinushi M, Baghdadi M, Chiba S, Yoshiyama H. Regulation of cancer
stem cell activities by tumor-associated macrophages. Am J Cancer Res.
2012;2(5):529–39.
6. Sylvester KG, Colnot S. Hippo/YAP, beta-catenin, and the cancer cell: a
“menage a trois” in hepatoblastoma. Gastroenterology. 2014;147(3):562–5.
7. Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, Jiang L, Fan B,
Terracciano L, Armeanu-Ebinger S, et al. Activation of beta-catenin and Yap1
in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
Gastroenterology. 2014;147(3):690–701.
8. Nussinov R, Tsai CJ, Jang H, Korcsmaros T, Csermely P. Oncogenic KRAS
signaling and YAP1/beta-catenin: similar cell cycle control in tumor
initiation. Semin Cell Dev Biol. 2016;58:79–85.
9. Cai J, Maitra A, Anders RA, Taketo MM, Pan D. Beta-catenin destruction
complex-independent regulation of Hippo-YAP signaling by APC in
intestinal tumorigenesis. Genes Dev. 2015;29(14):1493–506.
10. Bamodu OA, Huang WC, Tzeng DT, Wu A, Wang LS, Yeh CT, Chao TY.
Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin,
eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-
associated toxicity. Cancer Lett. 2015;364(2):125–34.
11. Liao YF, Rao YK, Tzeng YM. Aqueous extract of Anisomeles indica and its
purified compound exerts anti-metastatic activity through inhibition of
NF-kappaB/AP-1-dependent MMP-9 activation in human breast cancer
MCF-7 cells. Food Chem Toxicol. 2012;50(8):2930–6.
12. Ho JY, Hsu RJ, Wu CL, Chang WL, Cha TL, Yu DS, Yu CP. Ovatodiolide
targets beta-catenin signaling in suppressing tumorigenesis and
overcoming drug resistance in renal cell carcinoma. Evid Based
Complement Alternat Med. 2013;2013:161628.
13. Hsieh YJ, Tseng SP, Kuo YH, Cheng TL, Chiang CY, Tzeng YM, Tsai WC.
Ovatodiolide of Anisomeles indica exerts the anticancer potential on
pancreatic cancer cell lines through STAT3 and NF-kappaB regulation. Evid
Based Complement Alternat Med. 2016;2016:8680372.
14. Lu KT, Wang BY, Chi WY, Chang-Chien J, Yang JJ, Lee HT, Tzeng YM, Chang
WW. Ovatodiolide inhibits breast cancer stem/progenitor cells through
SMURF2-mediated downregulation of Hsp27. Toxins. 2016;8(5):E127.
15. Lin KL, Tsai PC, Hsieh CY, Chang LS, Lin SR. Antimetastatic effect and
mechanism of ovatodiolide in MDA-MB-231 human breast cancer cells.
Chem Biol Interact. 2011;194(2-3):148–58.
16. Wu T, Dai Y, Wang W, Teng G, Jiao H, Shuai X, Zhang R, Zhao P, Qiao L.
Macrophage targeting contributes to the inhibitory effects of embelin on
colitis-associated cancer. Oncotarget 2016;7(15):19548–58.
17. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J,
Chen X, Haigis K, Jegga AG, et al. Transcriptional recapitulation and
subversion of embryonic colon development by mouse colon tumor
models and human colon cancer. Genome Biol. 2007;8(7):R131.
18. Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, Van’t
Veer L, Tollenaar RA, Jackson DB, Agrawal D, et al. EMT is the dominant
program in human colon cancer. BMC Med Genomics. 2011;4(9):1755–8794.
19. Kim T, Yang SJ, Hwang D, Song J, Kim M, Kyum Kim S, Kang K, Ahn J, Lee D,
Kim MY, et al. A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced
cancer stemness. Nat Commun. 2015;6:10186.
20. Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS, Jang HJ, Park YY, Kopetz S, Kim
SS, Oh SC, et al. Significant association of oncogene YAP1 with poor
prognosis and cetuximab resistance in colorectal cancer patients. Clin
Cancer Res. 2015;21(2):357–64.
21. Xu H, Lai W, Zhang Y, Liu L, Luo X, Zeng Y, Wu H, Lan Q, Chu Z. Tumor-
associated macrophage-derived IL-6 and IL-8 enhance invasive activity of
LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner. BMC
Cancer. 2014;14:330.
22. Ho JY, Hsu RJ, Wu CL, Chang WL, Cha TL, Yu DS, Yu CP. Ovatodiolide
targets beta-catenin signaling in suppressing tumorigenesis and
overcoming drug resistance in renal cell carcinoma. Evid Based
Complement Alternat Med. 2013;161628(10):26.
23. Huang HC, Lien HM, Ke HJ, Chang LL, Chen CC, Chang TM.
Antioxidative characteristics of Anisomeles indica extract and
inhibitory effect of ovatodiolide on melanogenesis. Int J Mol Sci.
2012;13(5):6220–35.
24. Zhou Q, Peng RQ, Wu XJ, Xia Q, Hou JH, Ding Y, Zhou QM, Zhang X, Pang ZZ,
Wan DS, et al. The density of macrophages in the invasive front is inversely
correlated to liver metastasis in colon cancer. J Transl Med. 2010;8:13.
25. O’Hagan-Wong K, Nadeau S, Carrier-Leclerc A, Apablaza F, Hamdy R,
Shum-Tim D, Rodier F, Colmegna I. Increased IL-6 secretion by aged human
mesenchymal stromal cells disrupts hematopoietic stem and progenitor
cells’ homeostasis. Oncotarget. 2016;7(12):13285–96.
26. Waldner MJ, Foersch S, Neurath MF. Interleukin-6—a key regulator of
colorectal cancer development. Int J Biol Sci. 2012;8(9):1248–53.
27. Sica A, Rubino L, Mancino A, Larghi P, Porta C, Rimoldi M, Solinas G, Locati
M, Allavena P, Mantovani A. Targeting tumour-associated macrophages.
Expert Opin Ther Targets. 2007;11(9):1219–29.
28. Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol
Lett. 2009;123(2):97–102.
29. Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA,
Palmqvist R. The distribution of macrophages with a M1 or M2 phenotype
in relation to prognosis and the molecular characteristics of colorectal
cancer. PLoS One. 2012;7(10):e47045.
30. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, Akira S, Kotol
PF, Glass CK, Rosenfeld MG, et al. Macrophage/cancer cell interactions
mediate hormone resistance by a nuclear receptor derepression pathway.
Cell. 2006;124(3):615–29.
31. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages:
functional diversity, clinical significance, and open questions. Semin
Immunopathol. 2013;35(5):585–600.
32. Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M, Takeyama H.
Interleukin-6 released by colon cancer-associated fibroblasts is critical
for tumour angiogenesis: anti-interleukin-6 receptor antibody
suppressed angiogenesis and inhibited tumour-stroma interaction.
Br J Cancer. 2014;110(2):469–78.
33. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages
in tumour progression: implications for new anticancer therapies. J Pathol.
2002;196(3):254–65.
34. Cieslewicz M, Tang J, Yu JL, Cao H, Zavaljevski M, Motoyama K, Lieber A,
Raines EW, Pun SH. Targeted delivery of proapoptotic peptides to tumor-
associated macrophages improves survival. Proc Natl Acad Sci U S A. 2013;
110(40):15919–24.
35. Rao G, Wang H, Li B, Huang L, Xue D, Wang X, Jin H, Wang J, Zhu Y, Lu Y,
et al. Reciprocal interactions between tumor-associated macrophages and
CD44-positive cancer cells via osteopontin/CD44 promote tumorigenicity in
colorectal cancer. Clin Cancer Res. 2013;19(4):785–97.
36. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas.
J Clin Invest. 2012;122(3):787–95.
37. Tang X, Mo C, Wang Y, Wei D, Xiao H. Anti-tumour strategies aiming to
target tumour-associated macrophages. Immunology. 2013;138(2):93–104.
38. Covarrubias AJ, Aksoylar HI, Yu J, Snyder NW, Worth AJ, Iyer SS, Wang J,
Ben-Sahra I, Byles V, Polynne-Stapornkul T, et al. Akt-mTORC1 signaling
regulates Acly to integrate metabolic input to control of macrophage
activation. elife. 2016;5:e11612.
39. Barrett JP, Minogue AM, Falvey A, Lynch MA. Involvement of IGF-1 and Akt
in M1/M2 activation state in bone marrow-derived macrophages. Exp Cell
Res. 2015;335(2):258–68.
Huang et al. Journal of Hematology & Oncology  (2017) 10:60 Page 16 of 17
40. Byles V, Covarrubias AJ, Ben-Sahra I, Lamming DW, Sabatini DM, Manning
BD, Horng T. The TSC-mTOR pathway regulates macrophage polarization.
Nat Commun. 2013;4:2834.
41. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood
S, Rosenbluh J, Kim JW, et al. KRAS and YAP1 converge to regulate EMT and
tumor survival. Cell. 2014;158(1):171–84.
42. Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S,
Piazza S, Strano S, Del Sal G, Blandino G. YAP enhances the pro-proliferative
transcriptional activity of mutant p53 proteins. EMBO Rep. 2016;17(2):188–201.
43. Dotse E, Bian Y. Isolation of colorectal cancer stem-like cells.
Cytotechnology. 2016;68(4):609–19.
44. Rao YK, Fang SH, Hsieh SC, Yeh TH, Tzeng YM. The constituents of
Anisomeles indica and their anti-inflammatory activities. J Ethnopharmacol.
2009;121(2):292–6.
45. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity
screening. Nat Protoc. 2006;1(3):1112–6.
46. Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chiu HC, Dai YS,
Inoue H, et al. Tumor-associated macrophage-induced invasion and
angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2
induction. J Invest Dermatol. 2009;129(4):1016–25.
47. Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN, Yang SC, Ho CC, Chen CC,
Kuo YL, Lee PY, et al. Trifluoperazine, an antipsychotic agent, inhibits cancer
stem cell growth and overcomes drug resistance of lung cancer. Am
J Respir Crit Care Med. 2012;186(11):1180–8.
48. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic
assay of cells in vitro. Nat Protoc. 2006;1(5):2315–9.
49. McDonald JW, Pilgram TK. Nuclear expression of p53, p21 and cyclin D1 is
increased in bronchioloalveolar carcinoma. Histopathology. 1999;34(5):439–46.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Huang et al. Journal of Hematology & Oncology  (2017) 10:60 Page 17 of 17
